Table 1.
Major Phase III Trials of Extended Surgery for Resectable Gastric Cancer.
| Trial name | Published
year |
No. of
patients |
Eligible patients | Treatment groups | Morbidity
(%) |
5-year OS
(%) |
P-value |
|---|---|---|---|---|---|---|---|
| MRC trial (17), (18) | 1996, 1999 | 737 | cStage I-III | D1
D2 |
28
46 |
35
33 |
0.43 |
| Dutch trial (19), (20) | 1995, 2010 | 1078 | cStage I-III | D1
D2 |
25
43 |
45
47 |
0.53 |
| Taiwanese trial (21) | 2006 | 335 | cStage I-III | D1
D2 |
7.3
17.1 |
53.6
59.5 |
0.041 |
| JCOG9501 (7) | 2008 | 523 | cT3-T4b | D2 alone
D2 + PAND |
20.9
28.1 |
69.2
70.3 |
0.85 |
| JCOG9502 (8), (9) | 2006, 2015 | 167 | cT2-T4b
(cardia/subcardia) |
TH
LTA |
34.1
49.4 |
52.3
37.9 |
0.92* |
| JCOG0110 (10) | 2017 | 505 | cT2-T4b
(proximal) |
Spleen-preservation
Splenectomy |
16.7
30.3 |
76.4
75.1 |
0.025*
(for non-inferiority) |
| JCOG1001 (11) | 2018 | 1204 | cT3-T4a | Omentectomy alone
Bursectomy |
10.6
12.8 |
76.7
76.9 |
0.65* |
* one-sided p-value.
Abbreviations: OS, overall survival; HR, hazard ratio; PAND, para-aortic node dissection; TH, abdominal–transhiatal approach; LTA, left thoracoabdominal approach.